April 28th 2025
Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.
Watch the series now!
Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab
Precision Oncology: Why Payers Should Initiate CGP Coverage Now!